← Leaderboards
Benoit Christian Mouzon
Roskamp Institute, Inc.
$80,000
Attributed
$160,000
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $80K · FY2019–25$100K$75K$50K$25K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$160,000 · 1
VA$0 · 2
By mechanism
R03$160,000 · 1
I01$0 · 1
I21$0 · 1
Top collaborators
- Margarita Gutova2 shared
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingCellsPreventTraumatic Brain InjuryBrain InjuriesMolecularInjuryNeurobehavioralWhite MatterDoseMild Traumatic Brain InjuryMouse ModelCytokineAnimal ModelChronicAnimalsExposure ToTbi TreatmentCognitiveComplexBiologicalInsightLong-Term EffectsAnxiety
Grant awards (8)
Amnion cell secretome mediated therapy for traumatic brain injury$0
I01 · FY2025 · VA · contact PI
Amnion cell secretome mediated therapy for traumatic brain injury$0
I01 · FY2025 · VA · contact PI
Long-term effects of opioid use in a mouse model of repetitive mild traumatic brain injury$0
I21 · FY2023 · VA · contact PI
Amnion cell secretome mediated therapy for traumatic brain injury$0
I01 · FY2023 · VA · contact PI
Long-term effects of opioid use in a mouse model of repetitive mild traumatic brain injury$0
I21 · FY2021 · VA · contact PI
Development of Neural Stem Cell mediated therapy for repetitive mild TBI.$80,000
R03 · FY2020 · NS · contact PI
Long-term effects of opioid use in a mouse model of repetitive mild traumatic brain injury$0
I21 · FY2020 · VA · contact PI
Development of Neural Stem Cell mediated therapy for repetitive mild TBI.$80,000
R03 · FY2019 · NS · contact PI